NASDAQ$FULC
Fulcrum Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year of 2023, and provided a business update.
Fulcrum Therapeutics reported collaboration revenue of $0.9 million, R&D expenses of $19.0 million, and G&A expenses of $9.9 million for Q4 2023. The company's cash, cash equivalents, and marketable securities were $236.2 million as of December 31, 2023.
- On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024.
- Restart of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) underway.
- Cash, cash equivalents, and marketable securities were $236.2 million as of December 31, 2023.
- Collaboration revenue was $0.9 million for the fourth quarter of 2023.
Headline financials
Revenue & EPS history
Fulcrum Therapeutics · Revenue · Quarterly
$871K
Forward guidance
Fulcrum continues to expect that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating requirements into 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+5.2%
Avg return
Earnings day
+6.3%
Avg return
5 days after
+12.3%
Avg return
30 days after
62%
16 / 26 earnings
Positive
+142.5%
Q2 2021
Best reaction
-54.6%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -21.1% | -23.0% | -36.3% | |
| Q3 2025 | -6.6% | -9.8% | +9.4% | |
| Q1 2025 | +13.8% | +39.0% | +78.6% | |
| Q4 2024 | +0.0% | -3.0% | -16.5% | |
| Q3 2024 | -8.8% | -16.8% | +8.8% | |
| Q2 2024 | +7.1% | +0.6% | +1.7% | |
| Q1 2024 | +5.9% | +1.1% | +3.2% | |
| Q4 2023 | +6.1% | +12.9% | -3.0% | |
| Q3 2023 | +16.2% | -2.5% | +38.2% | |
| Q2 2023 | +3.4% | +5.5% | +49.7% | |
| Q1 2023 | +16.2% | -0.6% | -7.6% | |
| Q4 2022 | -28.0% | -36.6% | -62.0% | |
| Q3 2022 | +23.9% | +27.3% | +9.4% | |
| Q2 2022 | +8.4% | -6.2% | +7.1% | |
| Q1 2022 | -12.5% | -4.1% | -3.8% | |
| Q4 2021 | +17.4% | +37.8% | +113.9% | |
| Q3 2021 | -2.3% | -4.9% | -31.5% | |
| Q2 2021 | +142.5% | +175.3% | +233.9% | |
| Q1 2021 | +4.1% | +3.7% | -13.2% | |
| Q4 2020 | -17.7% | -17.4% | -17.8% | |
| Q3 2020 | +8.6% | +16.9% | +22.3% | |
| Q2 2020 | -54.6% | -55.5% | -54.7% | |
| Q1 2020 | +7.9% | +18.9% | +16.5% | |
| Q4 2019 | -2.2% | -27.8% | -49.4% | |
| Q3 2019 | +1.3% | +27.7% | +48.9% | |
| Q2 2019 | +7.2% | +6.1% | -25.5% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro